EUVIMEDEUVIMED entdecken
Crossref

Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect

Margherita Gardinetti, Valeria Barcella, Barbara Frigeni, Maura Frigo, Maria L Fusco, Mariarosa Rottoli

Neurological Disorders and Therapeutics · 2017

DOI: 10.15761/ndt.1000103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurological Disorders and Therapeutics, 2017. Verfasst von Margherita Gardinetti und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Gardinetti, M., Barcella, V., Frigeni, B., Frigo, M., Fusco, M. L., & Rottoli, M. (2017). Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect. Neurological Disorders and Therapeutics. https://doi.org/10.15761/ndt.1000103

Vancouver

Gardinetti M, Barcella V, Frigeni B, Frigo M, Fusco ML, Rottoli M. Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect. Neurological Disorders and Therapeutics. 2017. doi:10.15761/ndt.1000103

BibTeX
@article{Gardinetti2017,
  author = {Gardinetti, Margherita and Barcella, Valeria and Frigeni, Barbara and Frigo, Maura and Fusco, Maria L and Rottoli, Mariarosa},
  title = {Natalizumab-withdrawal-in-multiple-sclerosis-RR-patients-what-to-expect},
  journal = {Neurological Disorders and Therapeutics},
  year = {2017},
  doi = {10.15761/ndt.1000103}
}
Kostenlos starten →